Patents by Inventor Hwai Wen Chang

Hwai Wen Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11827704
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: November 28, 2023
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Publication number: 20230374702
    Abstract: A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.
    Type: Application
    Filed: June 27, 2023
    Publication date: November 23, 2023
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20230332135
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Application
    Filed: June 14, 2023
    Publication date: October 19, 2023
    Applicant: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11773509
    Abstract: A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: October 3, 2023
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11718844
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: August 8, 2023
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20230242662
    Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to CD46 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CD46 protein. Immunoconjugages, pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: June 15, 2021
    Publication date: August 3, 2023
    Applicant: BIOATLA, INC.
    Inventors: Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG, Jing WANG, Chao XING
  • Publication number: 20230235054
    Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to Nectin-4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Nectin-4 protein. Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: June 15, 2021
    Publication date: July 27, 2023
    Applicant: BIOATLA, INC.
    Inventors: Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG, Jing WANG, Chao XING, Haizhen LIU, Ana Paula CUGNETTI
  • Publication number: 20230192849
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.
    Type: Application
    Filed: October 27, 2022
    Publication date: June 22, 2023
    Inventors: William A. FRAZIER, Pamela T. MANNING, Gerhard FREY, Hwai Wen CHANG, Robert W. KARR
  • Publication number: 20230192858
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: November 17, 2022
    Publication date: June 22, 2023
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20230109218
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to HER2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to HER2 protein and multi-specific antibodies that bind to HER2 protein and CD3.
    Type: Application
    Filed: January 22, 2021
    Publication date: April 6, 2023
    Applicant: BioAtla, Inc.
    Inventors: Jay M. SHORT, Gerhard FREY, Hwai Wen Chang
  • Publication number: 20230072955
    Abstract: The present disclosure provides chimeric antigen receptors (CARs), and nucleic acids comprising nucleotide sequences encoding the CARs, that bind to HER2, and conditionally active biologic (CAB) CARs that bind to HER2. The present disclosure provides cells genetically modified to produce the CARs, delivery suspensions comprising these genetically modified cells, and methods for making such cells. The CARs of the present disclosure can be used in various methods, which are also provided, including methods for activating immune cells under certain conditions, and methods for performing adoptive cell therapy such as CAR therapy, for example CAR therapy against cancer.
    Type: Application
    Filed: January 23, 2021
    Publication date: March 9, 2023
    Applicants: Exuma Biotech Corp, BioAtla, Inc.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, JR., Anirban Kundu, Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20230013364
    Abstract: Combination therapies comprising antibody molecules that specifically bind to PD-1 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
    Type: Application
    Filed: December 13, 2021
    Publication date: January 19, 2023
    Inventors: Glenn Dranoff, Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Publication number: 20230000964
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 5, 2023
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • Patent number: 11542332
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: January 3, 2023
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20220403024
    Abstract: A non-naturally occurring polypeptide or isolated polypeptide having a ratio of at least 1.3 of an activity in an assay at a first pH in the presence of at least one species having a molecular weight of less than 900 a.m.u. and a pKa up to 4 pH units away from said first pH, to an activity in an assay at a second pH in the presence of the same at least one species. The species has a pKa between said first pH and said second pH and can be a small molecule. Also disclosed are pharmaceutical formulations including the polypeptide and uses thereof. Methods of producing conditionally active polypeptides are also disclosed.
    Type: Application
    Filed: August 19, 2022
    Publication date: December 22, 2022
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11472876
    Abstract: A non-naturally occurring polypeptide or isolated polypeptide having a ratio of at least 1.3 of an activity in an assay at a first pH in the presence of at least one species having a molecular weight of less than 900 a.m.u. and a pKa up to 4 pH units away from said first pH, to an activity in an assay at a second pH in the presence of the same at least one species. The species has a pKa between said first pH and said second pH and can be a small molecule. Also disclosed are pharmaceutical formulations including the polypeptide and uses thereof. Methods of producing conditionally active polypeptides are also disclosed.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 18, 2022
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20220315664
    Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: June 10, 2020
    Publication date: October 6, 2022
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Patent number: 11413340
    Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: August 16, 2022
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • Publication number: 20220169727
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Ror2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Ror2 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 2, 2022
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20220153835
    Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: September 30, 2021
    Publication date: May 19, 2022
    Inventors: Glenn DRANOFF, Frederic TRIEBEL, Chrystelle BRIGNONE, Walter A. BLATTLER, Jennifer Marie MATARAZA, Catherine Ann SABATOS-PEYTON, Hwai Wen CHANG, Gerhard Johann FREY